Connect with us

News

IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

gbafNews28

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive preclinical results demonstrating robust immunogenic and antibody responses from the majority of peptide epitopes. Based on these data, the Company has selected multiple peptide epitopes to be formulated within its DPX platform to form a vaccine candidate against the novel coronavirus, DPX-COVID-19.

These preclinical data are highly encouraging, showing that peptides formulated within the DPX platform have induced early and strong immunogenic response in an animal model. Notably, the antibody responses observed were equivalent or superior to levels achieved with DPX-RSV, which delivered a robust and sustained immune response in a Phase 1 study, said Marianne Stanford, Ph.D., Vice President Research and Development at IMV. Based on these results, our team has down selected a combination of peptides that have demonstrated immunogenicity and target several areas of the virus mechanism of entry in a non-overlapping fashion. DPX-COVID-19 is designed to focus the immune response on the weaknesses for the virus, to potentially increase its efficacy at preventing the infection and to efficiently inhibit virus entry into cells, thereby reducing the potential for immune escape, even in case of a mutation.

These results reflect the promise and versatility of our DPX platform technology, which has enabled our team to develop a new targeted vaccine candidate just two months after launching into development. Moreover, as we have shown across our clinical studies to date, our unique, targeted approach has elicited favorable results in sensitive populations, including older adult and immunocompromised patients who are most susceptible to this virus, said Frederic Ors, President and CEO at IMV. We are working closely with our collaborators to advance DPX-COVID-19 with urgency and remain on track to launch a Phase 1 clinical study in summer 2020.

IMV and its collaborators have rapidly advanced a DPX-based vaccine for COVID-19, since announcing plans in March. The Company used sequences of the virus and immunoinformatics to predict and identify several hundred epitopes, of which 23 were selected for validation in preclinical studies based on their biological relevance to the virus and potential to generate neutralizing antibodies against SARS-CoV-2. Preclinical studies have been ongoing since the beginning of April, with the goal to validate and down select the most promising peptide candidates targeting weaknesses of the virus.

In preclinical animal models, IMV evaluated all 23 peptides formulated within the DPX platform. The majority of peptide epitopes tested generated targeted antibody responses after the first and second dose, without requiring an adjuvant. Based on these results, IMV has selected an optimal combination of peptides based on the best antibody responses for each of the key mechanisms for attachment, fusion and entry of SARS-CoV-2 into human cells. The antibody responses observed were equivalent or superior to a DPX-based peptide epitope vaccine (DPX-RSV) used as a reference to evaluate the level of immunogenicity in these preclinical studies. DPX-RSV is a vaccine candidate against respiratory syncytial virus (RSV), another RNA respiratory virus, and has demonstrated high functional antibody titers (up to 100-fold increase over placebo maintained for at least 421 days1) in a Phase 1 clinical study in older adults (age 50-64).

Further vaccination-challenge preclinical assays in animal models are currently performed and IMV intends to publish results of preclinical studies in a peer-reviewed scientific journal in the coming weeks.

In April, IMV conducted a pre-Clinical Trial Application (CTA) meeting with Health Canada and is finalizing a design for a Phase 1 clinical study of DPX-COVID-19. The randomized, placebo-controlled study is expected to enroll approximately 84 healthy subjects in two age strata and to assess two different doses of DPX-COVID-19. The Company is on track to initiate this study in the summer of 2020.

About DPX-COVID-19

DPX-COVID-19 is IMVs vaccine candidate against the novel strain of coronavirus that is causing the current pandemic. It is a DPX-based formulation of multiple peptides of the SARS-CoV-2 that generated early and strong immune responses during the preclinical assays in animal models. A first-in-human Phase 1 clinical study is scheduled to initiate during summer 2020. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines. For more information, visit www.imv-inc.com

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Companys proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMVs lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19. Visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

Cautionary Language Regarding Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the Companys progress in developing a DPX-based vaccine candidate against COVID-19, the Companys belief that the DPX-based platform creates the opportunity for production of a COVID-19 vaccine, the Companys belief in the potential efficacy of its DPX-based vaccine against COVID-19, the potential benefits of a DPX-based vaccine against COVID-19 as compared to other potential vaccines, the anticipated timing of the Companys preclinical assays, studies and clinical trials and the release of any results therefrom related to its DPX-based vaccine against COVID-19 and the expected impact of COVID-19 on the Companys other clinical studies and trials and its operations generally. Such statements should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks and uncertainties affecting the Company and its products.

The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, the Companys ability to develop a DPX-based vaccine candidate against the COVID-19 through the successful and timely completion of preclinical assays, studies and clinical trials, the receipt of all regulatory approvals by the Company to commence and then continue clinical studies and trials, and, if successful, the commercialization of its proposed vaccine candidate related to COVID-19, the Companys ability to raise sufficient capital, including potentially through grant awards available in Canada, to fund such clinical studies and trials and the production of any COVID-19 vaccine, the ultimate applicability of any third-party research and studies in related coronavirus and SARS studies and sequencing, the Companys ability to enter into agreements with the proposed lead investigators to assist in the clinical development on its vaccine candidate related to COVID-19, the Companys ability to collaborate with governmental authorities with respect to such clinical development, the coverage and applicability of the Companys intellectual property rights to any vaccine candidate related to COVID-19, the ability of the Company to manufacture any vaccine candidate related to COVID-19 rapidly and at scale, the ability for the Company to accurately assess and anticipate the impact of COVID-19 on the Companys other clinical studies and trials and operations generally and other risks detailed from time to time in the Companys ongoing filings and in its annual information form filed with the Canadian regulatory authorities on SEDAR as www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Companys continuous disclosure documents which are available on SEDAR and on EDGAR.

1https://pubmed.ncbi.nlm.nih.gov/29617814/

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV

O: (902) 492-1819 ext : 1042

M: (514) 617-9481 E: [email protected]

Josh Rappaport, Director, Stern IR

O: (212) 362-1200

E: [email protected]

Media

Delphine Davan, Director of Communications, IMV

O: (902) 492-1819

E: [email protected]

News

Singaporean omnichannel e-tailer Iuiga to enhance user engagement and retention with Netcore Personalization

gbafNews28

– Iuiga is a leading direct-to-consumer Singapore homeware brand focusing on lifestyle products.

– Netcore to enable personalized omnichannel user experience across multiple channels and platforms for Iuiga

– Netcore’s AI-powered platform has already powered GoBear, Hermo, Sendo, Hnam, and Mapan

SINGAPORE, Oct. 29, 2020 /PRNewswire/ — Leading customer engagement and retention platform Netcore today announced the onboarding of one of South East Asia’s largest omnichannel e-tailer Iuiga to enable personalized user experience across platforms and channels.

Launched in 2017, IUIGA is known for its direct-to-consumer affordable, minimalist lifestyle products ranging from home and kitchen to apparels and electronics. Iuiga will leverage Netcore’s platform to enable a dynamically optimized, AI-powered personalized experience.

Jaslyn Chan, Founding Member and Chief Growth Officer, IUIGA: "We saw the Netcore platform and were impressed by the capabilities. Their deep expertise in the industry with some marquee names instilled us with the confidence we needed. I believe their proprietary AI-based personalization platform will be instrumental for the enhanced user experience and engagement we envision for our customers."

Netcore’s AI-powered platform has been the customer engagement and retention platform of choice for some of the biggest brands across the globe including GoBear, Hermo, Sendo, Hnam mobile, and Mapan (GoJek).

Kalpit Jain, Group CEO, Netcore Solutions said, "Iuiga is one of the most loved brands in SEA. It stands for quality and enhanced customer experience which resonated with the core philosophy of Netcore. Iuiga is redefining omnichannel retail in the region and we are excited to help drive the customer engagement fueled growth for them through dynamic and personalized experiences through our platform."

Logo – https://mma.prnasia.com/media2/1176346/Netcore_Solutions_Logo.jpg?p=medium600

Continue Reading

News

Delta Capita: Reinventing Data Sourcing for Chinese Entities – Karbon 8

gbafNews28

LONDON, Oct. 29, 2020 /PRNewswire/ — Now is the time to Reinvent. As we continue to navigate through the transformational changes taking place globally companies can take the opportunity to make positive, innovative changes to how business is being conducted today that will lead to long term benefits for both your teams and clients.

Karbon 8 is the latest proprietary technology solutions Delta Capita has brought to market, reinventing how we source and access KYC data for China entities. Learn more on how Delta Capita can partner and work with you in “reinventing” your value chain. Let’s Reinvent.
Karbon 8 is the latest proprietary technology solutions Delta Capita has brought to market, reinventing how we source and access KYC data for China entities. Learn more on how Delta Capita can partner and work with you in “reinventing” your value chain. Let’s Reinvent.

Karbon 8 is the latest proprietary technology solutions Delta Capita has brought to market, reinventing how we source and access KYC data for China entities. Launched earlier this year, Karbon 8 provides a comprehensive and real time data source for all Chinese client information.

Reinvention is about making improvements to something by looking at it in a different or a new way. At Delta Capita we work with our financial services clients to recognise the possibilities available for reinventing their existing operating models and how they can deliver it in a new way. Partnering with our clients, we work together to reinvent their value chain and consider the ways value is added along the chain, both to the products and services they offer, and what Delta Capita can perform on their behalf.

Through Karbon 8 clients can implement a cost-efficient operating model by automating and mutualizing the KYC data collection for Chinese entities. Karbon 8 aggregates and conducts initial analysis and comparisons of the sourced data in Chinese and then translates it into English as the final step, minimising the number of data discounting needed to be conducted. The data is sourced in real time, directly from the data sources in minutes, regardless of where the KYC analyst is located.

Delta Capita is a global provider of managed services, technology solutions and consulting. Delta Capita have a unique combination of experience in Financial Services and technology innovation capability, supported by an eco-system of proprietary technology solutions. Headquartered in London with offices around the world, Delta Capita work with the world’s top financial institutions to help them comply with regulations, simplify operations, reduce costs, and innovate their business models.

Learn more by visiting our website on how Delta Capita can partner and work with you in reinventing your value chain. Let’s Reinvent.

Media Enquiries: 
Leeya Hendricks 
CMO Delta Capita 
+44 (0)20 3890 4803 
[email protected]

Photo – https://mma.prnasia.com/media2/1322073/karbon_8.jpg?p=medium600
Logo – https://mma.prnasia.com/media2/1322074/Delta_Capita_Logo.jpg?p=medium600

 

Related Links :

https://deltacapita.com

Continue Reading

News

Centrapay Partners with Verifone to Launch New NZ Payment Service

gbafNews28
  • Centrapay to be available throughout New Zealand
  • No more per-transaction merchant fees for contactless payments
  • Partnership enables businesses to engage at the point of sale

AUCKLAND, NEW ZEALAND, Oct. 29, 2020 /PRNewswire/ — Centrapay is partnering with Verifone to deliver a new contactless payment platform that removes the per transaction fee businesses in New Zealand typically pay.


Centrapay and Verifone have combined multiple technologies to allow traditional and new financial applications to work together. The technology is centred on personalising the merchant and consumer payment experience.

Consumers and merchants can now – in real time – process contactless NZD payments, Giftstation Gift cards, accept digital assets, redeem Grab One vouchers, provide product and service feedback, offset carbon, utilise loyalty programmes, send or participate in surveys, and use digital identity solutions. And it all happens with an app and a QR code on any enabled Verifone payment device.  

Leveraging Verifone’s payment APIs, applications will be deployed to retailers remotely so that they can easily enable these new payment options. These applications use QR codes and/or NFC to communicate with Centrapay-supported mobile wallets, such as the Sylo Smart Wallet. This allows merchants to take payment in a range of new digital assets, gift cards, loyalty points, vouchers or NZD. It also leverages existing point of sale system investments, without the need to replace hardware or carry out bespoke and costly upgrades.

"If a customer and the merchant have a Centrapay-powered QR code or application, the two can now interact and engage in richer and more meaningful ways. Now customers can not only pay securely and easily but they can also now access a range of on-device options like providing feedback on a service or product, or offsetting the carbon footprint of their purchase," says Jerome Faury, CEO of Centrapay.   

Pete Hansen, GM at Verifone NZ says that the company has around 50 percent market share of payment devices deployed in New Zealand. It is committed to leading innovation for its merchants and focused on collaborating with companies like Centrapay to provide more flexibility and enhanced payment experiences for merchants and consumers.

The partnership also lets product producers or retailers offer value-added services to customers like the ability to pay with GrabOne vouchers, www.carbonclick.com or use Yabble to earn rewards or support offsetting your carbon footprint. 

ENDS

About Centrapay

Centrapay is about empowering merchants and enabling them to better connect and serve consumers with personalised payment experiences. Centrapay has unique capability for brands and businesses to easily create, distribute and transact Digital; where consumers, brands and businesses can engage and transact directly with each other without a third party taking a disproportionate cut. Centrapay focuses on unlocking value for merchants, whilst increasing compliance, efficiency and experience.

About Verifone

Verifone is transforming everyday transactions into new and engaging opportunities for merchants and consumers. Powered by a growing footprint of more than 35 million devices in more than 150 countries, our people are trusted experts working with the world’s best-known retail brands, financial institutions and payment providers. Verifone is connecting more products to an integrated solutions platform to better meet the evolving needs of our clients and partners. Built on a 39-year history of uncompromised security, we are committed to consistently solving the most complex payment challenges. More information at www.verifone.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News31 seconds ago

AIT Worldwide Logistics’ UK facilities earn priority customs clearance as Authorized Economic Operators

Global transportation logistics leader earns international mark of supply chain security, quality ITASCA, Ill., Oct. 29, 2020 /PRNewswire/ — The...

gbafNews28 gbafNews28
News31 seconds ago

Yum China Reports Third Quarter 2020 Results

Total Revenues grew 1%. System Sales grew 1% in constant currency Opened 312 new stores and reached 10,150 stores in...

gbafNews28 gbafNews28
News32 seconds ago

Centrapay Partners with Verifone to Launch New NZ Payment Service

Centrapay to be available throughout New Zealand No more per-transaction merchant fees for contactless payments Partnership enables businesses to engage...

gbafNews28 gbafNews28
News32 seconds ago

Delta Capita: Reinventing Data Sourcing for Chinese Entities – Karbon 8

LONDON, Oct. 29, 2020 /PRNewswire/ — Now is the time to Reinvent. As we continue to navigate through the transformational...

gbafNews28 gbafNews28
News32 seconds ago

Singaporean omnichannel e-tailer Iuiga to enhance user engagement and retention with Netcore Personalization

– Iuiga is a leading direct-to-consumer Singapore homeware brand focusing on lifestyle products. – Netcore to enable personalized omnichannel user...

gbafNews28 gbafNews28
News53 mins ago

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Ultra Petroleum Corp. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has...

gbafNews28 gbafNews28
News1 hour ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an...

gbafNews28 gbafNews28
News1 hour ago

COVID-19 Impact and Recovery Analysis – Global Medical Thermometers Market 2020-2024 | Evolving Opportunities with American Diagnostic Corp. and Ansell Ltd. | Technavio

The medical thermometers market is poised to grow by USD 104.82 million during 2020-2024 progressing at a CAGR of over...

gbafNews28 gbafNews28
News1 hour ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an...

gbafNews28 gbafNews28
News1 hour ago

USG ALERT: Shareholder Rights Firm Labaton Sucharow is Investigating USG Corporation (Former NYSE: USG) for Potential Securities Violations and Breach of Fiduciary Duty in Connection with its Merger with Gebr. Knauf Kg (“Knauf”)

Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against...